Results 241 to 250 of about 180,829 (383)

A 50‐year‐old man with a 12‐year history of extensive pachymeningeal thickening

Brain Pathology, EarlyView.
Alyssa M. Lee, Siddhartha Gaddamanugu, Kathyrn L. Eschbacher, Aishwarya Ravindran   +3 more
wiley   +1 more source

HPV42 – a human papillomavirus classified as a low‐risk type with oncogenic potential

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Human papillomavirus (HPV) type 42 is a rare HPV type currently classified as “low‐risk” and belongs to the alpha genus. It has primarily been detected in benign vulvar papillomas and is predominantly associated with benign lesions such as anogenital warts.
Sven Niklas Burmann, Ulrike Wieland, Steffi Silling, Frank Oellig, David Chromy, Julia Hyun, Thilo Gambichler, Alexander Kreuter   +7 more
wiley   +1 more source

CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells

, 2016
S Jiang, Xunqiang WANG, Zhiming Zhang, Sun L, Yeong‐Shiau Pu, Yao Hu, Jie Li, Liu Y, Y Zhang, W Zhang   +9 more
openalex   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

A real-world 10-year follow-up analysis of survival and safety of CD20-targeted therapy in patients with Waldenstrom macroglobulinemia. [PDF]

Front Oncol
Zhang H, Huang X, Zhu Y, Zheng Z, Zhan R, Wang S.   +5 more
europepmc   +1 more source

A role of CD20+ T cells in early multiple sclerosis [PDF]

Marina Rode von Essen, Marie Mathilde Hansen, Sahla El Mahdaoui, Victoria Hyslop Hvalkof, R. Hansen, Jørgen E. Nielsen, Jette Lautrup Frederiksen, Finn Sellebjerg   +7 more
openalex   +1 more source

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Blood, 1994
Mitchell, Reff, K. Carner, K. Chambers, P. Chinn, J. Leonard, Ron Raab, R. Newman, N. Hanna, D. Anderson   +9 more
semanticscholar   +1 more source

Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell, Carolyn Owen, Mona Shafey, Sarah Perry, Nanette Cox‐Kennett, Russell Sterrett, Anthea Peters, Robert Puckrin   +7 more
wiley   +1 more source

Real-world single-center analysis of efficacy and safety in newly diagnosed marginal zone lymphoma. [PDF]

Clin Exp Med
Zhou X, Ruan J, Shi Y, Shan N.
europepmc   +1 more source

CD20 Antigen Status [PDF]

, 2020
openaire   +1 more source